[go: up one dir, main page]

MX2017015765A - Regimenes de dosificacion inmunoterapeutica que comprenden pomalidomida y un anticuerpo anti-cs1 para el tratamiento de cancer. - Google Patents

Regimenes de dosificacion inmunoterapeutica que comprenden pomalidomida y un anticuerpo anti-cs1 para el tratamiento de cancer.

Info

Publication number
MX2017015765A
MX2017015765A MX2017015765A MX2017015765A MX2017015765A MX 2017015765 A MX2017015765 A MX 2017015765A MX 2017015765 A MX2017015765 A MX 2017015765A MX 2017015765 A MX2017015765 A MX 2017015765A MX 2017015765 A MX2017015765 A MX 2017015765A
Authority
MX
Mexico
Prior art keywords
immunotherapeutic
antibody
cancer treatment
dosage regimes
include pomalidomide
Prior art date
Application number
MX2017015765A
Other languages
English (en)
Other versions
MX391581B (es
Inventor
Darron Robbins Michael
Lee Mulligan Christopher
Blake Bartlett Justin
Original Assignee
Squibb Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb Bristol Myers Co filed Critical Squibb Bristol Myers Co
Publication of MX2017015765A publication Critical patent/MX2017015765A/es
Publication of MX391581B publication Critical patent/MX391581B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención descrita en este documento se relaciona con regímenes de dosificación terapéuticos y de combinación de los mismos para su uso en la mejora de la eficacia terapéutica de los anticuerpos anti-CS1 en combinación con uno o más agentes inmunoterapéuticos.
MX2017015765A 2015-06-29 2016-06-28 Regimenes de dosificacion inmunoterapeutica que comprenden pomalidomida y un anticuerpo anti-cs1 para el tratamiento de cancer. MX391581B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562185968P 2015-06-29 2015-06-29
US201562239965P 2015-10-11 2015-10-11
US201562262574P 2015-12-03 2015-12-03
PCT/US2016/039723 WO2017003990A1 (en) 2015-06-29 2016-06-28 Immunotherapeutic dosing regimens comprising pomalidomide and an anti-cs1 antibody for treating cancer

Publications (2)

Publication Number Publication Date
MX2017015765A true MX2017015765A (es) 2018-04-13
MX391581B MX391581B (es) 2025-03-04

Family

ID=56409706

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017015765A MX391581B (es) 2015-06-29 2016-06-28 Regimenes de dosificacion inmunoterapeutica que comprenden pomalidomida y un anticuerpo anti-cs1 para el tratamiento de cancer.

Country Status (20)

Country Link
US (2) US10925867B2 (es)
EP (2) EP3950065A1 (es)
JP (1) JP6754785B2 (es)
CN (1) CN107949425A (es)
BR (1) BR112017027692A2 (es)
CA (1) CA2990478A1 (es)
CY (1) CY1124543T1 (es)
DK (1) DK3313528T3 (es)
EA (1) EA035888B1 (es)
ES (1) ES2886657T3 (es)
HR (1) HRP20211478T1 (es)
HU (1) HUE056491T2 (es)
LT (1) LT3313528T (es)
MX (1) MX391581B (es)
PL (1) PL3313528T3 (es)
PT (1) PT3313528T (es)
RS (1) RS62352B1 (es)
SI (1) SI3313528T1 (es)
SM (1) SMT202100567T1 (es)
WO (1) WO2017003990A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10034872B2 (en) * 2014-08-22 2018-07-31 Celgene Corporation Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
HRP20211478T1 (hr) * 2015-06-29 2021-12-24 Bristol-Myers Squibb Company Imunoterapijski režimi doziranja koji obuhvaćaju pomalidomid i anti-cs1 antitijelo za liječenje raka
EP3488851A1 (en) * 2018-10-03 2019-05-29 AVM Biotechnology, LLC Immunoablative therapies

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA204125A (en) 1920-09-21 Sylvester Pratt Edwin Gramophone operated toy
US819826A (en) 1905-12-14 1906-05-08 Frank R Welcher Stanchion.
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
JP2001523958A (ja) 1997-03-21 2001-11-27 ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド 免疫療法のｃｔｌａ−４結合ペプチド
PL210435B1 (pl) 1998-12-23 2012-01-31 Amgen Fremont Inc Ludzkie przeciwciała monoklonalne wiążące się z CTLA-4
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
ATE254615T1 (de) 1999-02-22 2003-12-15 Biotechnolog Forschung Gmbh C-21 modifizierte epothilone
US7629360B2 (en) 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
KR20020047132A (ko) 1999-08-24 2002-06-21 메다렉스, 인코포레이티드 인간 씨티엘에이-4 항체 및 그의 용도
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP1261376A1 (en) 2000-01-27 2002-12-04 Genetics Institute, LLC Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof
US7041499B2 (en) 2001-12-12 2006-05-09 University Of North Texas Health Science Center Immuno activation of CS1 receptor in natural killer cells to inhibit tumor cell growth
CN1981761B (zh) * 2002-05-17 2011-10-12 细胞基因公司 使用免疫调节性化合物用于制备治疗和控制癌症和其它疾病药物中的应用及组合物
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
SI1558648T1 (sl) 2002-10-17 2012-05-31 Genmab As Človeška monoklonalna protitelesa proti CD
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
US6958115B2 (en) 2003-06-24 2005-10-25 The United States Of America As Represented By The Secretary Of The Navy Low temperature refining and formation of refractory metals
EP2439273B1 (en) 2005-05-09 2019-02-27 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
CN101534860B (zh) * 2006-08-07 2013-03-27 艾伯特生物治疗学公司 使用抗cs1-抗体治疗多发性骨髓瘤的组合物和方法
EP2069478A2 (en) 2006-08-07 2009-06-17 PDL BioPharma, Inc. Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells
MX2009001441A (es) 2006-08-07 2009-07-06 Facet Biotech Corp Metodos para tratar mieloma multiple usando terapias de combinacion basadas en anticuerpos anti-cs1.
JP2010500370A (ja) * 2006-08-07 2010-01-07 ピーディーエル バイオファーマ，インコーポレイティド 多発性硬化症を処置するための抗ｃｓ１抗体を用いる組成物および方法
CN102216332A (zh) 2008-10-31 2011-10-12 艾伯特生物治疗学公司 抗-cs1抗体用于治疗罕见淋巴瘤的用途
SI3351240T1 (sl) 2009-05-19 2019-08-30 Celgene Corporation Formulacije 4-amino-2-(2,6-dioksopiperidin-3-il)izoindolin-1,3-diona
EP2493486A1 (en) 2009-10-30 2012-09-05 University Of Arkansas For Medical Science Use of autologous effector cells and antibodies for treatment of multiple myeloma
US20130052158A1 (en) 2009-10-30 2013-02-28 University Of Arkansas For Medical Science Use of autologous effector cells for treatment of multiple myeloma
US9506481B1 (en) 2013-01-31 2016-11-29 Daniel Theobald High force hydraulic actuator
US20160331698A1 (en) * 2014-01-13 2016-11-17 University Of Central Florida Research Foundation, Inc. Fullerene compounds as antioxidant therapy
US10034872B2 (en) * 2014-08-22 2018-07-31 Celgene Corporation Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
WO2016070089A2 (en) 2014-10-31 2016-05-06 Abbvie Biotherapeutics Inc. Anti-cs1 antibodies and antibody drug conjugates
HRP20211478T1 (hr) * 2015-06-29 2021-12-24 Bristol-Myers Squibb Company Imunoterapijski režimi doziranja koji obuhvaćaju pomalidomid i anti-cs1 antitijelo za liječenje raka

Also Published As

Publication number Publication date
SMT202100567T1 (it) 2021-11-12
EP3950065A1 (en) 2022-02-09
SI3313528T1 (sl) 2021-11-30
EA035888B1 (ru) 2020-08-27
MX391581B (es) 2025-03-04
BR112017027692A2 (pt) 2018-10-09
US10925867B2 (en) 2021-02-23
US20210154183A1 (en) 2021-05-27
ES2886657T3 (es) 2021-12-20
EP3313528A1 (en) 2018-05-02
CN107949425A (zh) 2018-04-20
JP6754785B2 (ja) 2020-09-16
EP3313528B1 (en) 2021-08-04
HRP20211478T1 (hr) 2021-12-24
RS62352B1 (sr) 2021-10-29
JP2018522881A (ja) 2018-08-16
HUE056491T2 (hu) 2022-02-28
EA201890035A1 (ru) 2018-06-29
CA2990478A1 (en) 2017-01-05
DK3313528T3 (da) 2021-09-20
PT3313528T (pt) 2021-09-16
US20180185348A1 (en) 2018-07-05
LT3313528T (lt) 2021-10-11
CY1124543T1 (el) 2022-07-22
PL3313528T3 (pl) 2021-12-13
WO2017003990A1 (en) 2017-01-05

Similar Documents

Publication Publication Date Title
CO2021001912A2 (es) Composiciones anti-cd112r y métodos
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
MX2017013178A (es) Terapia de combinacion para cancer.
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
BR112019005908A2 (pt) uso de combinação de anticorpo anti-pd-1 e inibidor de vegfr na preparação de fármaco para tratamento de cânceres
MX2016015363A (es) Terapias de combinacion para el tratamiento de cancer.
MX2019008208A (es) Métodos para tratar el cáncer con anticuerpos anti-tim-3.
CO2017000754A2 (es) Anticuerpo monoclonal anti-ctla4 o fragmento de unión a antígeno del mismo, y una composición farmacéutica del mismo
MX384141B (es) Métodos para monitorear y terapias para usarse en tratar el cáncer.
CL2015002472A1 (es) Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4.
BR112018014016A2 (pt) combinação de um agonista de ox40 e um agonista de anticorpo monoclonal 4-1bb para tratamento de câncer
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
ECSP18096095A (es) Anticuerpos a la alfa-sinucleína y usos de los mismos
CL2016001131A1 (es) Uso de una combinación farmacéutica que comprende un compuesto inhibidor de mdm2 y uno o más agentes activos adicionales para el tratamiento del cáncer y composiciones farmacéuticas que comprenden dichas combinaciones.
BR112016026993A2 (pt) combinação de um anticorpo anti-ccr4 e um agonista 4-1bb para tratar câncer
UY35964A (es) Anticuerpos humanos para pd?1
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
MX2016013457A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
MX2018006152A (es) Metodos para el tratamiento de cancer utilizando inhibidores b-raf e inhibidores de punto de control inmunologico.
DK3624837T3 (da) Anti-fgfr2-antistoffer i kombination med kemoterapeutiske midler til kræftbehandling
DK4339615T3 (da) Anti-PD-1-antistof til anvendelse i behandlingen af kræft
IL269844A (en) Dosing regimens and related compositions and methods
CL2017002983A1 (es) Terapia combinada de un anticuerpo anti-cd-20 con un inhibidor de bcl-2 y un inhibidor de mdm2
CL2016001753A1 (es) Anticuerpo monoclonal humanizado que se une específicamente a netrina-1, composiciones farmacéuticas y usos del anticuerpo para el tratamiento del cáncer
CY1125536T1 (el) Συνθεσεις για τη θεραπεια της αμυλοειδωσης